drugset / Trial / NCT05665088
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
RandomizedParallel-groupDouble-blindTreatment
Summary
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 168 doses within a 12-week treatment period.
Timeline
- Start
- 2022-12-14
- Primary completion
- 2023-09-11
- Completion
- 2023-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 40 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 60 ug | Other |